文献速递先天性心脏病外科瓣膜外科

法洛四联症术后肺动脉瓣置换的更新荟萃分析

Pulmonary Valve Replacement in Tetralogy of Fallot: An Updated Meta-Analysis.
PubMed 文献 · Ann Thorac Surg · 2020-12-27

PVR术后30天、5年、10年汇总死亡率分别为0.87%、2.7%、6.2%,5年和10年再次PVR率分别为3.7%和16.8%。PVR后脑钠肽下降,但QRS时限、心肺运动试验及心室纵向应变无显著变化;术前右室 indexed 舒张末期和收缩末期容积越大,术后右室容积正常化机会越低。

要点

  • PVR术后30天、5年、10年死亡率分别为0.87%、2.7%、6.2%。
  • PVR后脑钠肽下降,但QRS时限和心肺运动试验无显著改善。
  • 术前右室容积越大,术后右室容积正常化机会越低。

核心结论

  • 该更新荟萃分析为法洛四联症修复后患者行肺动脉瓣置换的获益提供了证据。

主要发现

  • PVR术后30天汇总死亡率为0.87%(63/7253,80项研究)。
  • PVR术后5年汇总死亡率为2.7%(132/4952,37项研究)。
  • PVR术后10年汇总死亡率为6.2%(510/2765,15项研究)。
  • PVR术后5年和10年再次PVR率分别为3.7%(141/3755,23项研究)和16.8%(172/3035,16项研究)。
  • PVR后QRS时限、心肺运动试验结果及右室和左室纵向应变无显著变化,脑钠肽下降;术前 indexed 右室舒张末期和收缩末期容积越大,术后右室容积正常化机会越低。

临床怎么用

  • 对于法洛四联症修复后肺动脉反流患者,PVR可降低脑钠肽,但术前右室显著扩大者术后右室容积正常化机会较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The benefits of pulmonary valve replacement (PVR) for pulmonary insufficiency in patients with repaired tetralogy of Fallot are still incompletely understood, and optimal timing remains challenging. METHODS: We systematically reviewed databases (PubMed/MEDLINE, Embase, Cochrane Central Register of Controlled Trials /Cochrane Controlled Trials Register, ClinicalTrials.gov, Scientific Electronic Library Online, Literatura Latino Americana em Ciências da Saúde, and Google Scholar) and reference lists of relevant articles for studies about PVR in repaired tetralogy of Fallot patients that reported any of the following outcomes: mortality and redo PVR rates, right ventricular (RV) and left ventricular measures, QRS duration, cardiopulmonary exercise test results, or brain natriuretic peptide. In addition to calculating the pooled treatment effects using a random-effects meta-analysis, we evaluated the effect of preoperative measures on PVR outcomes using meta-regressions. RESULTS: Eighty-four studies involving 7544 patients met the eligibility criteria. Pooled mortality at 30 days, 5 years, and 10 years after PVR was 0.87% (63 of 7253 patients, 80 studies), 2.7% (132 of 4952 patients, 37 studies), and 6.2% (510 of 2765 patients, 15 studies), respectively. Pooled 5- and 10-year redo PVR rates were 3.7% (141 of 3755 patients, 23 studies) and 16.8% (172 of 3035 patients, 16 studies), respectively. The results of the previous meta-analysis could be confirmed. In addition, we demonstrated that after PVR (1) QRS duration, cardiopulmonary exercise test results, and RV and left ventricular measures longitudinal strain do not significantly change; (2) brain natriuretic peptide decreases; and (3) greater indexed RV end-diastolic and end-systolic volumes are associated with lower chances of RV volume normalization after PVR. CONCLUSIONS: This updated meta-analysis provides evidence about the benefits of PVR.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Van den Eynde J, Sá MPBO, Vervoort D, et al. Pulmonary Valve Replacement in Tetralogy of Fallot: An Updated Meta-Analysis. Ann Thorac Surg. 2020. PMID: 33378694. doi:10.1016/j.athoracsur.2020.11.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。